Compare AbCellera Biologics Inc (ABCL) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Southern Copper Corp — how do they compare? AbCellera Biologics Inc trades at $9.86 (market cap $2.99B), while Southern Copper Corp trades at $195.52 (market cap $164.21B). The key difference: Southern Copper Corp is far larger — about 54.9× AbCellera Biologics Inc's market cap, and Southern Copper Corp pays a 2.26% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | SCCO | |
|---|---|---|
Market Cap | $2.99B | $164.21B |
Sector | Health | Basic Materials |
52-Week High | $9.76 | $218.85 |
52-Week Low | $2.78 | $93.70 |
Enterprise Value | $2.58B | $165.50B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
SCCO trades at $200.11, up 0.53% today, near its pivot point of $201. The stock exhibits strong profitability with a 35.87% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights its rally fueled by strong H1 results and higher copper prices, though production declines and premium valuations are noted concerns (Zacks Investment Research, 2026-08-11).
Outlook is mixed; robust earnings growth and AI-driven copper demand present upside, but high valuation ratios and analyst skepticism pose risks. The consensus price target of $153.64 suggests significant downside from current levels, indicating caution is warranted despite positive technical and fundamental trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
